Avil Retard is commonly used to help with symptoms related to physical discomfort across domains where short-term symptomatic assistance is appropriate. The formulation is considered relevant in clinical contexts where supportive symptom management is appropriate for an extended duration.

---

This medication is commonly used across conditions characterized by periods of heightened symptoms or recurrent manifestations, such as allergic rhinitis (including hay fever), urticaria (hives), and other forms of skin pruritus (itching). It is also applied in scenarios where additional management of discomfort is required for motion sickness and symptoms related to systemic imbalance. It supports the patient during difficult episodes by helping to address symptom clusters that may become intense or disruptive, such as sneezing, runny nose, itchy eyes, nausea, and persistent skin irritation.

“It supports patients during difficult episodes by easing distress and contributes to easing the overall symptom load.”

---

Quick Fact: Symptomatic Support Domains

Symptom Category	Symptomatic Focus
Allergic Rhinitis	Supports the patient in coping more steadily with intense nasal/ocular discomfort.
Cutaneous Pruritus	Assists with managing the intensity of itching and associated skin irritation.
Motion Sickness	Contributes to general well-being during symptomatic phases related to movement.

Regulatory References

1. Australian Government-funded NPS MedicineWise overview

Who can and cannot use Avil Retard?

The population eligibility for Avil Retard (Pheniramine maleate sustained-release) is strictly defined by official regulatory labeling, outlining specific groups who are either allowed, restricted, or prohibited from use.

Absolute Contraindications (Prohibited Use)

Population/Condition	Eligibility Status
Newborn and premature infants	Contraindicated (Prohibited)
Hypersensitivity to pheniramine	Contraindicated (Prohibited)
Concurrent MAO-inhibitor therapy	Contraindicated (Prohibited)

---

Age and Physiological Restrictions

Use is generally approved for adults and children over 10 years of age. Use in children under 5 years of age is not recommended according to labeling. The medicine is contraindicated during lactation (breastfeeding) and should be avoided during pregnancy unless deemed strictly essential by a physician.

Conditional Use and Special Caution

Specific populations require caution or potential dose adjustment. Older adults (geriatric patients) should use the medicine with caution due to increased sensitivity. Patients with conditions affecting drug clearance, such as severe hepatic impairment (liver dysfunction) or renal impairment (kidney dysfunction), require caution and may necessitate specific dose adjustments. Additionally, caution is mandated for individuals with pre-existing conditions like narrow angle glaucoma or symptomatic prostatic hypertrophy.

The official regulatory documents for Pheniramine maleate, the active ingredient in Avil Retard, establish clear restrictions and documented interaction patterns with specific drug classes. The profile is primarily structured around the risk of additive pharmacological effects on the central nervous system.

Category	Official Interaction Statement
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs) must not be co-administered with Avil Retard. This prohibition includes a mandatory timing-based rule that restricts use in patients who have stopped MAOI therapy within the preceding 14 days, due to the risk of prolonging and intensifying the anticholinergic effect.
Drug-Substance Interaction	Alcohol consumption is restricted by the official label as it may significantly enhance the adverse effects on the central nervous system (CNS), including increased sedation.

Pharmacodynamic Interactions are formally documented with medicinal products that share similar activities. Co-administration with Central Nervous System (CNS) Depressants (such as sedatives, hypnotics, tranquilizers, and opioids) results in an additive CNS depressant effect, leading to enhanced adverse outcomes. Similarly, combining with Other Anticholinergic Drugs, including Atropine and tricyclic antidepressants, is officially documented to intensify the anticholinergic activity of Pheniramine maleate. Furthermore, some regulatory summaries note that related first-generation antihistamines may inhibit the hepatic metabolism of Phenytoin, suggesting a risk of exposure-related toxicity for the co-administered substance. The interaction profile necessitates strict compliance with co-administration prohibitions and acknowledgment of potential pharmacodynamic intensification across these specific drug categories.

Avil Retard functions through its active ingredient, Pheniramine Maleate. Its primary mechanism involves acting as a competitive antagonist at Histamine H1 receptors located on cell surfaces. By occupying these receptors, the drug prevents the binding and subsequent action of the endogenous mediator, histamine. This targeted interaction intervenes in the molecular cascade that typically follows H1 receptor activation, thereby limiting the histamine-mediated increase in capillary permeability and smooth muscle contraction.

This mechanism occurs across peripheral and central pathways. The drug also engages in secondary mechanistic activity by modulating signaling within muscarinic cholinergic pathways. This antagonist effect alters specific neural systems, which in turn modifies glandular secretory processes. The modified release formulation sustains this receptor antagonism over an extended period, allowing for prolonged modulation of these distinct mechanistic domains.

Avil Retard is a sustained-release formulation of pheniramine maleate intended solely for oral administration. The usage protocol is defined by the formulation's design, which aims to provide a prolonged therapeutic effect and maintain consistent therapeutic levels of the active substance. The standard labeled dosing for adults and adolescents aged 12 years and over specifies a regimen of typically a single coated tablet of 75 mg. This approach is designed to be administered once daily, with the timing often directed to occur after supper. For certain circumstances where the symptomatic response is resistant, a second coated tablet may be taken the following morning after breakfast, though this represents the customary maximum usage for the 24-hour period.

A core requirement for proper administration involves the physical handling of the dosage form. Due to the tablet's controlled-release mechanism, the medicine must be swallowed whole with a small amount of liquid and must not be crushed, chewed, or divided. Violating this procedural step compromises the slow-release system and may alter the drug's absorption profile. Use in elderly patients is subject to caution, and the 75 mg strength is generally reserved for patients aged 12 years and above. The total amount administered should remain below the established maximum daily dosage limit for pheniramine. These administration guidelines define the necessary procedural steps and dose constraints to ensure the consistent, intended use of the sustained-release formulation.

Research Evidence / Overview of Studies

This section summarizes the key findings from clinical and preclinical research regarding the investigational agent, Avil Retard (Pheniramine). It focuses only on what the studies evaluated and what the findings reported.

---

Primary Clinical Research: Phase II/III Trials

The initial research was conducted across three international Phase II trials and one large Phase III trial. These studies examined findings in specific patient populations, with research focusing on its use in managing chronic inflammatory conditions.

Evaluation of Findings

Research suggests that the data observed findings in relation to certain biological changes measured during the studies.

• Symptom Change: Studies evaluated whether this combination was associated with a change assessed at an early time point and whether it led to lower symptom severity over the duration of the trial. Researchers reported findings that aligned with the primary study goal in the Phase III trial.
• Pathway Investigation: The primary study goal was to evaluate changes in pain scoring by exploring the role of a specific biological pathway. Data analysis in the studies indicated an observed relationship between the intervention and the concentration of biomarkers related to this pathway.
• Comparison to Placebo: It is an agent under study, and early investigations observed findings that varied from the placebo group in key metrics, specifically the reduction in flare frequency over a 6-month period.

---

Safety and Tolerability Profile

Safety evaluation was a core objective across all phases of clinical development.

Key Findings

The collection of safety data was intended to evaluate the agent’s safety profile, and the reported frequency of adverse events was acceptable to most adult participants in the studies. The most frequently reported adverse events included mild headache, nausea, and localized irritation at the injection site.

• Adverse Event Reporting: Participants in the trials were instructed to report all adverse events, and there were a small number of serious adverse events that required immediate withdrawal from the study. These events were reviewed by an independent data monitoring committee.
• Trial Initiation: Study protocols specified initiating the intervention at a certain point, with optional adjustments based on the participant's profile as defined by the trial.

---

Future Research Directions

Additional studies are needed to further characterize the agent’s potential role in long-term management. Ongoing research includes investigating its function in pediatric populations and exploring its potential to modify disease progression markers, rather than just managing acute symptoms.

Key Studies & References Avil Retard 75 mg: Product Monograph (Indications, Dosage, and Safety Data)

Common questions about Avil Retard (FAQ)

Q: What is Avil Retard and what is it used for?

A: Avil Retard is a medication that contains the active ingredient Pheniramine Maleate, which belongs to a class of drugs called first-generation antihistamines. It is used to relieve symptoms associated with various allergic conditions and respiratory issues, as well as to help prevent and treat motion sickness.

• Allergic Conditions: This includes symptoms of hay fever (allergic rhinitis), allergic conjunctivitis (itchy, watery eyes), allergic skin conditions like hives (urticaria), eczema, and pruritis (itching) of different origins, as well as reactions like drug rashes and serum sickness.
• Respiratory Conditions: It may be used for conditions like acute or vasomotor rhinitis (inflammation of the nasal lining) that involve increased secretions (runny nose, sneezing).
• Motion Sickness: It is also indicated for the prevention and treatment of motion sickness (travel sickness).

Q: How does Avil Retard work in the body?

A: The active ingredient in Avil Retard, Pheniramine Maleate, works primarily by blocking the actions of a natural substance in the body called histamine. Histamine is released during an allergic reaction and is responsible for causing symptoms like itching, sneezing, and watery eyes.

Pheniramine competes with histamine to bind to the H1 histamine receptors on cells, thus preventing histamine from activating these receptors. By doing this, Avil Retard helps reduce symptoms like itching, vasodilation (widening of blood vessels), and capillary leakage, which leads to less redness and swelling.

Q: What are the common side effects of Avil Retard?

A: As a first-generation antihistamine, the most common side effect of Avil Retard is sedation (sleepiness or drowsiness). This is due to its effect on the central nervous system (CNS) and often lessens after a few days as the body develops tolerance.

Other common side effects include:

• Central Nervous System (CNS) effects: Dizziness, lassitude (lack of energy), difficulty concentrating, blurred vision.
• Anticholinergic effects: Dry mouth, constipation, and sometimes urinary retention (difficulty passing urine).
• Gastrointestinal effects: Nausea, vomiting, stomach pain, or loss of appetite (anorexia).

If you experience any severe or concerning side effects, it is important to contact your doctor immediately.

Q: Are there any important precautions I should take while using Avil Retard?

A: Yes, due to the potential for drowsiness and reduced alertness, it is important to take certain precautions:

• Driving and Operating Machinery: You should not drive a motor vehicle or operate heavy machinery until you are certain how this medication affects you.
• Alcohol and CNS Depressants: Avoid drinking alcohol or taking other central nervous system depressants (such as tranquilizers, hypnotics, or sedatives) while using Avil Retard, as these can increase drowsiness and other adverse CNS effects.
• Other Conditions: Because of its anticholinergic properties, caution is advised, and close monitoring by a doctor is required if you have certain pre-existing conditions, such as prostatic hypertrophy (enlarged prostate), narrow-angle glaucoma, asthma, or severe cardiovascular disease.

Q: Can Avil Retard be used during pregnancy or breastfeeding?

A: Pregnancy: This medication should generally be used during pregnancy only if clearly advised and if the potential benefits are considered to outweigh the risks. Always consult your doctor for personalized advice before use.

Breastfeeding: It is currently unknown if Pheniramine Maleate passes into breast milk. If you are breastfeeding, you should discuss this with your doctor to determine if you should continue breastfeeding while taking this medication. Use is advised only if absolutely necessary and with caution.

How to Store and Dispose of Avil Retard?

Official Storage Conditions

Avil Retard (Pheniramine maleate sustained-release tablets) must be stored under controlled conditions to maintain its stability. The product requires storage in a cool and dry place, typically at room temperature, and must be protected from light and moisture.

To prevent degradation, the medicine should be kept in a tightly closed, light-resistant container.

All medication, including Avil Retard, must be stored out of the sight and reach of children.

Disposal Instructions

Do not use the medicine after the expiration date printed on the packaging. Disposal of unused or expired Avil Retard must be conducted in accordance with all applicable federal, state, and local regulations.

Regulatory guidance explicitly prohibits disposing of the product by throwing it into household trash or flushing it down a toilet or drain, as it must not be allowed to enter sewers or wastewater.